HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gel Tech Extending Zicam With Allergy Relief Homeopathic Nasal Gel

This article was originally published in The Tan Sheet

Executive Summary

Gel Tech is expanding the Zicam brand with a treatment for allergic rhinitis, or hay fever. The homeopathic spray product is shipping to major food, drug and mass market chains nationwide now.

You may also be interested in...



Quigley Likely To Prove Gum Tech's Zicam Infringes Its Patent, Judge Finds

Quigley Corp. is likely - but not certain - to succeed in its claim of patent infringement against Gum Tech, Philadelphia federal court Judge Stewart Dalzell finds in his April 19 memorandum and order.

Gel Tech Zicam Zinc Nasal Spray Is "Remedy For The Common Cold"

Gel Tech's Zicam zinc gel nasal spray is a "fast-acting remedy for the common cold," product labeling says. Launched in January as a "homeopathic nasal gel," the product "helps reduce the duration of the common cold" and "helps relieve the symptoms of the common cold," packaging states.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel